| Recruiting | Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis NCT06441006 | University of California, San Francisco | Phase 2 / Phase 3 |
| Not Yet Recruiting | Registry on the Effectiveness and Safety of the 9-month MDR-END Treatment Regimen in Korean Patients with FQ-s NCT06674291 | Korea Otsuka Pharmaceutical Co., Ltd. | — |
| Not Yet Recruiting | Test to Treat TB: Impact of Sputum Sequencing-guided Individualised Therapy on Outcomes in Drug-resistant Tube NCT05007795 | University of Cape Town | N/A |
| Unknown | Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Mult NCT05555303 | Rwanda Biomedical Centre | Phase 2 |
| Active Not Recruiting | Linezolid Dosing Strategies in Drug-Resistant TB NCT05007821 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Recruiting | Hotspots, Households and Hospitals: Enhanced Drug-resistant Tuberculosis Case Finding in Namibia NCT05022238 | University of Namibia | — |
| Active Not Recruiting | Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB NCT03828201 | Boston University | Phase 2 |
| Unknown | A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug NCT05306223 | Beijing Chest Hospital | Phase 4 |
| Active Not Recruiting | Bioneer Q-RFIA Clinical Evaluation NCT05117788 | Foundation for Innovative New Diagnostics, Switzerland | — |
| Completed | A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant NCT04179500 | Global Alliance for TB Drug Development | Phase 2 |
| Completed | Clinical Evaluation of tNGS for Diagnosis of DR-TB NCT04239326 | Foundation for Innovative New Diagnostics, Switzerland | — |
| Terminated | PredictEndTB Signature for Individualizing Treatment in Multidrug-Resistant Tuberculosis NCT04783727 | Research Center Borstel | N/A |
| Active Not Recruiting | Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens NCT05871489 | Harvard Medical School (HMS and HSDM) | — |
| Completed | Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resist NCT03896685 | Médecins Sans Frontières, France | Phase 3 |
| Terminated | Safety of RUTI® Vaccination in MDR-TB Patients NCT02711735 | Archivel Farma S.L. | Phase 2 |
| Completed | Xpert MTB/XDR Clinical Evaluation Trial NCT03728725 | Foundation for Innovative New Diagnostics, Switzerland | — |
| Completed | Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and NCT03338621 | Global Alliance for TB Drug Development | Phase 2 / Phase 3 |
| Unknown | Feasibility of Centralized Therapeutic Drug Monitoring of Fluoroquinolones in Multi-Drug Resistant Tuberculosi NCT03409315 | University Medical Center Groningen | — |
| Completed | Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tub NCT03086486 | Global Alliance for TB Drug Development | Phase 3 |
| Terminated | The Individualized M(X) Drug-resistant TB Treatment Strategy Study NCT03237182 | Centre for the AIDS Programme of Research in South Africa | Phase 4 |
| Completed | DIAgnostics for Multidrug Resistant Tuberculosis in Africa NCT03303963 | Dissou AFFOLABI | — |
| Completed | Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s) NCT02589782 | Medecins Sans Frontieres, Netherlands | Phase 2 / Phase 3 |
| Completed | Evaluating Newly Approved Drugs for Multidrug-resistant TB NCT02754765 | Médecins Sans Frontières, France | Phase 3 |
| Completed | Study of TB Lesions Obtained in Therapeutical Surgery NCT02715271 | Fundació Institut Germans Trias i Pujol | — |
| Recruiting | Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen NCT02354014 | Janssen Research & Development, LLC | Phase 2 |
| Completed | Drug Concentrations in the Treatment of MDR-TB Related to Minimum Inhibitory Concentrations NCT02816931 | Karolinska Institutet | — |
| Completed | Treatment Shortening of MDR-TB Using Existing and New Drugs NCT02619994 | Seoul National University Hospital | Phase 2 |
| Completed | Nosocomial Transmission of MDR-TB in Bucharest, Romania NCT02413931 | Research Center Borstel | — |
| Completed | Expand New Drugs for TB [endTB] NCT03259269 | Partners in Health | — |
| Completed | An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR- NCT02365623 | Janssen Pharmaceutical K.K. | Phase 2 |
| Completed | Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB NCT01918397 | Boston University | Phase 2 |
| Completed | Biomarkers for Therapy Response in Drug-resistant Tuberculosis NCT02597621 | Research Center Borstel | — |
| Completed | Global Consortium for Drug-resistant Tuberculosis Diagnostics NCT02170441 | University of California, San Diego | — |
| Recruiting | Training Protocol on the Natural History of Tuberculosis NCT01212003 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Tuberculosis in China NCT01071603 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683 NCT02573350 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 |
| Completed | A Trial to Evaluate OPC 67683 in Participants With Pulmonary Sputum Culture-positive, Multidrug-resistant Tube NCT00685360 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 |
| Completed | Operational Assessment of Laboratory Information System for MDR-TB in Lima, Peru NCT01201941 | Brigham and Women's Hospital | — |
| Completed | High-Dose Isoniazid Adjuvant Therapy for Multidrug Resistant Tuberculosis NCT00513396 | GSVM Medical College | Phase 2 / Phase 3 |